ResultsĪ total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients. The role of thiamine in critically ill septic patient has been addressed in multiple studies however, it’s role in COVID-19 patients is still unclear. Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism it improves the immune system function and has shown to reduce the risk of several diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |